Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Newlink Genetics Cor (NLNK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 69,229
  • Shares Outstanding, K 37,220
  • Annual Sales, $ 28,710 K
  • Annual Income, $ -71,950 K
  • 36-Month Beta 1.55
  • Price/Sales 2.49
  • Price/Cash Flow N/A
  • Price/Book 0.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.33
  • Number of Estimates 3
  • High Estimate -0.25
  • Low Estimate -0.43
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +10.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.84 +16.58%
on 11/14/18
2.48 -13.51%
on 11/02/18
-0.03 (-1.15%)
since 10/15/18
3-Month
1.84 +16.58%
on 11/14/18
3.21 -33.18%
on 08/30/18
-0.62 (-22.28%)
since 08/15/18
52-Week
1.84 +16.58%
on 11/14/18
10.41 -79.39%
on 01/04/18
-6.58 (-75.43%)
since 11/15/17

Most Recent Stories

More News
NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 (rVSVDG-ZEBOV-GP) to U.S. Food and Drug Administration

In 2014 the Company entered into a license agreement with Merck to develop, manufacture and commercialize NewLink Genetics' Ebola vaccine candidate

MRK : 74.43 (+0.46%)
NLNK : 2.12 (+13.98%)
Analysis: Positioning to Benefit within Mercury, Lincoln Electric, Sprint, Fred's, NewLink Genetics, and El Paso Electric -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mercury Systems Inc (NASDAQ:MRCY),...

EE : 56.51 (-1.77%)
S : 6.12 (-0.49%)
LECO : 83.20 (+0.65%)
FRED : 3.21 (+0.63%)
MRCY : 49.52 (+2.10%)
NLNK : 2.12 (+13.98%)
Is the Options Market Predicting a Spike in NewLink Genetics (NLNK) Stock? (revised)

Investors need to pay close attention to NewLink Genetics (NLNK) stock based on the movements in the options market lately.

NLNK : 2.12 (+13.98%)
Is the Options Market Predicting a Spike in Hertz NewLink Genetics (NLNK) Stock?

Investors need to pay close attention to Hertz NewLink Genetics (NLNK) stock based on the movements in the options market lately.

NLNK : 2.12 (+13.98%)
CORRECTED: NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings

In a release issued under the same headline yesterday by NewLink Genetics Corporation (NASDAQ:NLNK), the balance statement included in the press release was incorrect. The corrected release follows:

NLNK : 2.12 (+13.98%)
NewLink Genetics (NLNK) Reports Q3 Loss, Lags Revenue Estimates

NewLink (NLNK) delivered earnings and revenue surprises of 52.38% and -94.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

NLNK : 2.12 (+13.98%)
NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings

NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the third quarter 2018 and reviewed recent highlights and upcoming milestones.

NLNK : 2.12 (+13.98%)
NewLink Genetics Announces Oral Presentation at the 2018 American Society of Hematology (ASH) Annual Meeting

NewLink Genetics Corporation (NASDAQ:NLNK) announced today that an abstract with data pertaining to the use of the Company's investigational immuno-oncology molecule, indoximod, in combination therapy...

NLNK : 2.12 (+13.98%)
NewLink Genetics (NLNK) Q3 Earnings Preview: What to Expect

NewLink (NLNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NLNK : 2.12 (+13.98%)
NewLink Genetics to Host Its Third Quarter 2018 Financial Results Conference Call on November 1, 2018

NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its third quarter 2018 financial results on Thursday, November 1, 2018. The company has scheduled a conference call for 4:30...

NLNK : 2.12 (+13.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade NLNK with:

Business Summary

NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink...

See More

Key Turning Points

2nd Resistance Point 2.13
1st Resistance Point 1.99
Last Price 2.13
1st Support Level 1.78
2nd Support Level 1.71

See More

52-Week High 10.41
Fibonacci 61.8% 7.14
Fibonacci 50% 6.13
Fibonacci 38.2% 5.11
Last Price 2.13
52-Week Low 1.84

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar